Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + pirfenidone
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hydroxychloroquine + pirfenidone is a combination therapy consisting of the immunomodulatory antimalarial agent hydroxychloroquine and the antifibrotic agent pirfenidone. This combination is being explored for the management of Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD), particularly in patients with a Usual Interstitial Pneumonia (UIP) pattern. Hydroxychloroquine, a 4-aminoquinoline derivative, acts by increasing lysosomal pH and inhibiting toll-like receptors (TLR7 and TLR9), which reduces the activation of the innate immune system and manages the articular manifestations of rheumatoid arthritis. Pirfenidone is an orally active small molecule that exerts antifibrotic and anti-inflammatory effects by inhibiting the production of transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha), thereby reducing fibroblast proliferation and collagen synthesis. The combination aims to simultaneously address the systemic autoimmune inflammation and the progressive pulmonary fibrosis characteristic of RA-ILD.
- Other names
- HCQ + pirfenidone
02
Targets
TLR7 (Toll-like receptor 7)TLR9 (Toll-like receptor 9)TGFB (GARP–latent transforming growth factor beta 1 complex)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on hydroxychloroquine + pirfenidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + pirfenidone.